NASDAQ:NLSP
NLS Pharmaceutics AG Stock News
$0.168
-0.0100 (-5.61%)
At Close: Jun 25, 2024
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
08:38am, Thursday, 20'th Jun 2024
NLS Pharmaceutics (NASDAQ: NLSP ) stock is down on Thursday but that's only after the clinical-stage biopharmaceutical company's shares underwent a massive rally on Tuesday. Shares of NLSP stock clos
Why Is NLS Pharmaceutics (NLSP) Stock Up 163% Today?
07:54am, Tuesday, 18'th Jun 2024
NLS Pharmaceutics (NASDAQ: NLSP ) stock is rocketing higher on Tuesday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 73 million share
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
08:30am, Tuesday, 11'th Jun 2024
ZURICH, SWITZERLAND / ACCESSWIRE / June 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
05:00pm, Friday, 19'th Apr 2024
ZÜRICH, SWITZERLAND / ACCESSWIRE / April 19, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discov
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
04:30pm, Friday, 22'nd Mar 2024
ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discov
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
01:40pm, Wednesday, 20'th Mar 2024
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
07:30am, Wednesday, 20'th Mar 2024
The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacolo
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
08:00am, Thursday, 14'th Mar 2024
ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance
07:00am, Monday, 11'th Mar 2024
ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
07:30am, Friday, 23'rd Feb 2024
ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the dis
Notice of Deficiency with Nasdaq Continued Listing Requirements
04:30pm, Friday, 12'th Jan 2024
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disco
NLS Pharmaceutics CEO Issues Letter to Shareholders
04:30pm, Friday, 29'th Dec 2023
ZURICH, SWITZERLAND / ACCESSWIRE / December 29, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery
Why Is NLS Pharmaceutics (NLSP) Stock Down 24% Today?
09:06am, Monday, 04'th Dec 2023
NLS Pharmaceutics (NASDAQ: NLSP ) stock is taking a beating on Monday as the company's shares come down from a rally on Friday. The news that sent shares of NLSP stock higher on Friday concerned an e
The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential treatment of narcolepsy and other neuro-degenerative disorders, and al
NLS Pharmaceutics Announces Election of Additional Board Members
07:30am, Tuesday, 28'th Nov 2023
Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disorders Professor Flor
